Pamicell Rises 5.26% Amid Uptrend in COVID-19 (Diagnostics/Treatment/Vaccine Development) Theme

On the 22nd, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.07% compared to the previous day, showing strength, while Parmicell, a related stock attracting attention, surged by 5.26% compared to the previous day. Parmicell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.

[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme



According to the analysis by Thinkpool Robo Algorithm RASSI, Parmicell ranked 14th out of 47 stocks in the quant financial ranking by exceeding the theme’s average scores in growth, stability, and profitability. This can be interpreted as Parmicell having a relatively high investment attractiveness compared to other stocks in the theme from a financial perspective.

[Table] Top stocks by financial score within the theme


※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.